Drug Profile


Alternative Names: BPC 15; BPC-157; PCO-02; PL 10; PLD 116; PLD 14736

Latest Information Update: 30 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Zagreb
  • Developer PharmaCotherapia; PLIVA d.d.
  • Class Anti-inflammatories; Antiallergics; Antiulcers; Cytoprotectives; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ulcerative colitis

Most Recent Events

  • 01 Oct 2015 Phase-I clinical trials in Ulcerative colitis (In volunteers) in Mexico (PO) (NCT02637284)
  • 01 Jun 2005 Data presented at Digestive Disease Week-2005 (DDW-2005) have been added to the adverse events and Inflammatory bowel disorders therapeutic trials sections
  • 03 Dec 2003 A preclinical study has been added to the Peptic Ulcer Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top